8-K: Plus Therapeutics Announces Q1 2024 Financial Results and Business Updates, Secures $19.25M Private Placement and $3M DoD Grant

Plus Therapeutics reported its Q1 2024 financial results, highlighted by a $19.25 million private placement, a $3 million Department of Defense grant, and the acquisition of a leptomeningeal metastases diagnostic portfolio.

Summary

• Plus Therapeutics announced its financial results for the first quarter of 2024, ending March 31, 2024.
• The company closed a private placement financing on May 9, 2024, securing initial gross proceeds of $7.25 million and up to $19.25 million in aggregate.
• Plus Therapeutics received a $3 million grant award from the Department of Defense to fund a Phase 1 trial of rhenium (186Re) obisbemeda in children with brain cancer.
• The company acquired assets to commercialize the CNSide leptomeningeal metastases diagnostic.
• The company's cash balance was $3 million at the end of Q1 2024, compared to $8.6 million at the end of 2023.
• Grant revenue for Q1 2024 was $1.7 million, up from $0.5 million in Q1 2023.
• The total operating loss for Q1 2024 was $3.3 million, compared to $4.8 million in the same period of 2023.
• Net loss for Q1 2024 was $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, for the same period the prior year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful private placement, the DoD grant, and the acquisition of a new diagnostic portfolio. However, the decrease in cash balance and the ongoing net loss temper the overall sentiment.

Positives

• The company successfully secured a significant private placement of up to $19.25 million.
• The $3 million grant from the Department of Defense will help fund a key clinical trial.
• The acquisition of the CNSide diagnostic portfolio expands the company's offerings.
• Grant revenue increased significantly year-over-year, indicating successful funding efforts.
• The company reduced its operating loss and net loss per share compared to the same period last year.

Negatives

• The company's cash balance decreased from $8.6 million at the end of 2023 to $3 million at the end of Q1 2024.
• The company still reported a net loss of $3.3 million for the quarter.

Risks

• The company's product candidates are in early stages of development, and clinical trial results are uncertain.
• The company's ability to raise additional capital is crucial for continued operations.
• There are risks associated with regulatory requirements, market conditions, and competition in the cancer therapeutics field.
• The company faces risks related to intellectual property protection and potential cybersecurity attacks.

Future Outlook

The company intends to focus on moving lead programs to pivotal trials, key data readouts, building a commercial-ready supply chain, and leveraging the CNSide acquisition to create stockholder value. They also anticipate FDA feedback in the second half of 2024 for the ReSPECT-PBC investigational new drug application.

Management Comments

• We have made substantial business progress thus far in 2024 and we believe that the Company is well positioned to meet its 2024 milestones, said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.
• For the remainder of the year, we intend to focus on creating stockholder value through moving lead programs to pivotal trials, key data readouts, building out a commercial ready supply chain, and leveraging the new opportunities provided by the recent CNSide acquisition.

Industry Context

This announcement reflects the ongoing efforts in the pharmaceutical industry to develop targeted radiotherapeutics for central nervous system cancers. The acquisition of the CNSide diagnostic portfolio aligns with the trend of integrating diagnostics with therapeutics for personalized medicine. The company's focus on clinical trials and regulatory milestones is typical for a clinical-stage pharmaceutical company.

Comparison to Industry Standards

• The $19.25 million private placement is a significant capital raise for a company of this size, comparable to other biotech firms in early clinical stages.
• The $3 million DoD grant is a notable achievement, reflecting the potential of their technology in addressing unmet medical needs, similar to other companies receiving government funding for innovative therapies.
• The acquisition of the CNSide diagnostic portfolio is a strategic move, similar to other companies that are integrating diagnostics with therapeutics to improve patient outcomes.
• The reported operating loss of $3.3 million is within the range of other clinical-stage biotech companies, but the cash burn rate is a concern that needs to be monitored.
• The company's focus on multiple clinical trials and regulatory milestones is consistent with industry standards for companies developing novel therapeutics.

Management Changes

Stakeholder Impact

• Shareholders may view the private placement and grant as positive developments, but the cash burn rate and net loss may cause concern.
• Employees may be encouraged by the company's progress and expansion.
• Patients may benefit from the development of new therapies and diagnostics.
• Suppliers may see increased business opportunities with the company's growth.

Next Steps

• Presentations at upcoming scientific conferences including SNMMI, SNO/ASCO, and SNO.
• FDA Type C meeting for ReSPECT-LM scheduled for June 10, 2024.
• Anticipate FDA feedback in the second half of 2024 for ReSPECT-PBC IND.
• Complete ReSPECT-LM Phase 1 dose escalation trial enrollment.
• Report results of preclinical combination studies of rhenium (186Re) obisbemeda with PD-1 and PD-L1 checkpoint inhibitors.
• Secure contract with second GMP manufacturing supplier.

Key Dates

Keywords

radiotherapeutics, brain cancer, glioblastoma, leptomeningeal metastases, rhenium (186Re) obisbemeda, CNSide, clinical trials, private placement, Department of Defense grant, financial results